Kowa Company Limited

Koichi Arai

Yasushi Saito

Akio Iwasaki

Hideo Yoshizaki

Hiroyuki Yamazaki

The present invention is drawn to a DNA encoding a novel LDL receptor-analog. LDL receptors participate in lipoprotein metabolism, which is a critical factor in the onset of arteriosclerosis. The invention provides DNA having the nucleotide sequences shown by SEQ ID NOS: 1 and 5, which encode rabbit and human LDL receptor analog proteins having the sequences shown in SEQ ID NOS: 3 and 7 respectively.

LDL receptor analog protein and DNA coding therefor

A human placenta-derived antiocoagulating substance is prepared by homogenizing a human plancenta, subjecting the resulting homogenate to centrifugal separation, extracting the thus-obtained sediment with a chelating agent, and then separating and purifying the extract. The substance has a molecular weight of 73,000.+-.2,000 as measured in reduced and non-reduced states by SDS-polyacrylamide gel electrophoresis. Its isoelectric point ranges from 6.2 to 6.6 as measured by isoelectric column electrophoresis using an ampholyte. It is inactivated by a heat treatment at 50.degree. C. for 30 minutes, is stable in a pH range of 5.5-8.5 (37.degree. C.) and is also stable in plasma at 37.degree. C. for 15 minutes. It can prolong the recalcification time, prothrombin time and activated partial thromboplastic time.

Growing community of inventors

Urawa, Japan

Koichi Arai